BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Emerging Biotech

Corcept Therapeutics Submits NDA for Relacorilant to FDA for Cushing’s Syndrome Treatment

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocr...

January 01, 2025 | News

Exicure Signs MOU to Acquire GPCR USA and Advance Collaborative Research in Drug Development

Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR ...

December 30, 2024 | News

Ractigen Therapeutics Doses First Patient in Phase I Trial of RAG-17 for SOD1-Linked ALS

Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing RNA-based innovative therapies, today announced the successful dosin...

December 25, 2024 | News

New Therapeutics Venture GEMMABio Secures $34M in Seed Funding to Accelerate Gene Therapy Initiatives

Significant international investment defies sector trend GEMMA Biotherapeutics ("GEMMABio") – a new therapeutics company founded by gene therapy pio...

December 24, 2024 | News

India’s Biotech Boom: Supriya Kashikar on Startups, Innovation, and the Road to 2030

India’s biotechnology sector is on a trajectory to reach $300 billion by 2030, fueled by a dynamic startup ecosystem, robust government initiatives l...

December 17, 2024 | Interview

Brazilian Biotech Nintx Secures $10 Million Series A Funding to Advance Multifactorial Disease Therapies

Startup funding includes a Series A round led by venture capital firms Pitanga, Ecoa Capital and MOV Investimentos, along with a grant from FINEP ...

December 16, 2024 | News

Hong Kong’s Viva Biotech Expands Global Footprint with Strategic Boston Branch Launch

Viva Biotech Holdings Group ("Viva Biotech") announced the official establishment of its new branch in Boston, USA. As a global leader in drug re...

December 12, 2024 | News

Duke Street Bio Initiates Phase I Trial of Highly Selective PARP1 Inhibitor DSB2455 for Solid Tumours

Duke Street Bio Ltd, a precision medicine biotech developing next-generation small molecule cancer therapies, is pleased to announce that the first patient...

December 12, 2024 | News

Skyhawk Therapeutics Gains Australian Approval to Extend SKY-0515 Huntington’s Disease Trial to 12 Weeks

Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 trial in patients with Hun...

December 10, 2024 | News

Nona Biosciences Partners with Kodiak Sciences to Accelerate Multi-Target Antibody Therapies for Ophthalmic Diseases

Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody disc...

December 10, 2024 | News

Qi Biodesign Secures $75M in Series A Funding to Propel Next-Gen Genome Editing Innovations

Qi Biodesign, a biotechnology company pioneering next-generation genome editing technologies, announced the completion of its Series A funding round. The c...

December 09, 2024 | News

Cambrex Partners with Eli Lilly to Accelerate Biotech Innovation

Cambrex, a leading global contract development and manufacturing organization (CDMO), announced that it has signed an agreement with Eli Lilly and Company ...

December 06, 2024 | News

Duality Biologics and GSK Forge $1 Billion Partnership for Next-Generation ADC Candidate

Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjugate (AD...

December 04, 2024 | News

Serina Therapeutics Secures $10 Million Equity Financing from JuvVentures to Advance Parkinson's Therapy

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, announced a $10 million equity fi...

December 03, 2024 | News

Stay Connected